Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GHSR | Q92847 | 1/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035847 | 0.87 | MEN1 (1.00) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL12878224 | 0.87 | MEN1 (0.74) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL18962990 | 0.86 | ALDH1A1 (0.72) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL8752442 | 0.86 | LMNA (0.71) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL31681256 | 0.84 | ACLY (0.70) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL4734474 | 0.81 | LMNA (0.68) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL20577926 | 0.81 | LMNA (0.71) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL4730290 | 0.81 | LMNA (0.71) | KMT2AMEN1LMNATSHRHTT | |
| SCHEMBL8752432 | 0.80 | PLAU (0.76) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL4736605 | 0.80 | GHSR (0.60) | KMT2AMEN1LMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | KMT2A 2025/4885MEN1 4622/4885LMNA 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.